A Clinical Trial for Post Traumatic Stress Disorder (MATTER)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00554177
Recruitment Status : Completed
First Posted : November 6, 2007
Last Update Posted : March 17, 2016
Information provided by (Responsible Party):
Antonia New, Icahn School of Medicine at Mount Sinai

November 2, 2007
November 6, 2007
March 17, 2016
September 2007
September 2008   (Final data collection date for primary outcome measure)
Clinical Administered PTSD Scale(CAPS) [ Time Frame: once a week over eight weeks ]
Same as current
Complete list of historical versions of study NCT00554177 on Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
A Clinical Trial for Post Traumatic Stress Disorder
Mifepristone After Trauma to Enhance Resilience
he purpose of this study is to test whether a medication, called mifepristone (commonly known as the ³Morning-After-Pill²), can help to prevent emotional problems after someone has survived a traumatic experience. We are studying this medication for the treatment of Post-traumatic Stress disorder (PTSD.

PTSD is an emotional illness that can develop in people after they have experienced a traumatic event. It involves symptoms such as poor sleep, nightmares about the trauma, unwanted daytime memories of the trauma (flashbacks), jumpiness, and trouble looking forward to things in the future. Once people develop PTSD, the symptoms tend to last a very long time.

We are testing the idea that mifepristone, which blocks the effect of the hormones progesterone and cortisol, will help treat PTSD. Progesterone is a hormone made in the bodies of both men and women and its main role is in regulating the menstrual cycle and in pregnancy. Cortisol is also a hormone made in the body of both men and women and helps the body respond to stress. Cortisol also has a role in making emotional memories more intense than other memories. We are testing whether blocking the effect of cortisol with mifepristone as you recall your trauma may be able to decrease the intensity of your traumatic memories. This medication will not completely block out your memories of the traumatic experience but may decrease how much your thoughts are drawn back to the memory of the traumatic event.

Phase 1
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Post Traumatic Stress Disorder (PTSD)
  • Drug: Medicane (mifepristone)
    2 doses of 1200mg, Administered 2-3 days apart
  • Drug: Placebo
    2 doses of 1200mg, administered 2-3 days apart
  • Experimental: 1
    Medicane (mifepristone)
    Intervention: Drug: Medicane (mifepristone)
  • Placebo Comparator: 2
    Intervention: Drug: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
December 2008
September 2008   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Male or Female
  • Between 18 and 65 years old
  • Have experienced one or more traumatic events within the last year €Examples for traumatic events include physical or sexual assault, combat, natural disasters, witnessing death or injury of another person, bereavement €Currently experiencing severe symptoms of anxiety including flashbacks and intrusive memories of the traumatic event. €Not currently pregnant or intending to become pregnant. If sexually active, participants must be using an approved form of birth control
  • Medically healthy
  • Not currently taking psychiatric medications

Exclusion Criteria:

  • > Lifetime or current diagnosis of schizophrenia or other psychotic disorder, bipolar disorder, or current Axis I disorder (except for major depression secondary to the PTSD)
  • Current evidence or history of significant unstable medical illness or organic brain impairment, including stroke, CNS tumor, demyelinating disease, cardiac, pulmonary, gastrointestinal, or renal or hepatic impairment.
  • Patient who in the investigator¹s judgment pose a current suicidal or homicidal risk
  • DSM-IV substance abuse or dependence within the past 90 days
  • Patient has been taking psychotropic medication in the last 2 weeks (5 weeks for fluoxetine) prior to screening. Psychotropic medications in the last 2 weeks prior to screening, fluoxetine in last 5 weeks.
  • Treatment with any other concomitant medication with primarily CNS activity
  • Treatment with any medication that the PI considers not acceptable for this study.
  • Patient regularly, or on average, drinks more than a) 28 units of alcohol per week for male patients, or b) 21 units of alcohol per week for female patients (1 unit = 1/2 pint of beer, or 1 glass of wine, or 1 measure of spirit)
  • Pregnancy or lactation*
  • Patient is currently receiving evidenced-based structured psychotherapy (e.g., cognitive-behavioral therapy, exposure therapy).
Sexes Eligible for Study: All
18 Years to 65 Years   (Adult)
Contact information is only displayed when the study is recruiting subjects
United States
GCO# 07-0900
Not Provided
Plan to Share IPD: No
Antonia New, Icahn School of Medicine at Mount Sinai
Antonia New
Not Provided
Principal Investigator: Antonia New, MD Icahn School of Medicine at Mount Sinai
Icahn School of Medicine at Mount Sinai
March 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP